Literature DB >> 22528196

Single gene disorders associated with stroke: a review and update on treatment options.

Hurmina Muqtadar1, Fernando D Testai.   

Abstract

OPINION STATEMENT: Single gene stroke disorders are rare but important to consider in the differential diagnosis of cryptogenic stroke. The identification of these disorders has a significant prognostic value and may be instrumental in the development of an appropriate stroke prevention plan. In this review we summarize the clinical features, diagnosis, and treatment of the following single gene disorders: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL); Fabry disease; sickle cell disease; and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS).

Entities:  

Year:  2012        PMID: 22528196     DOI: 10.1007/s11936-012-0179-4

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  40 in total

Review 1.  Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome.

Authors:  Kristin M Santa
Journal:  Pharmacotherapy       Date:  2010-11       Impact factor: 4.705

2.  MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL.

Authors:  M O'Sullivan; J M Jarosz; R J Martin; N Deasy; J F Powell; H S Markus
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

3.  Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy.

Authors:  Sohei Yanagawa; Nobuo Ito; Kunimasa Arima; Shu-ichi Ikeda
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

4.  Effects of gender on the phenotype of CADASIL.

Authors:  Bence Gunda; Dominique Hervé; Ophelia Godin; Martina Bruno; Sonia Reyes; Nassira Alili; Christian Opherk; Eric Jouvent; Marco Düring; Marie-Germaine Bousser; Martin Dichgans; Hugues Chabriat
Journal:  Stroke       Date:  2011-10-27       Impact factor: 7.914

5.  Population prevalence of the MELAS A3243G mutation.

Authors:  Neil Manwaring; Michael M Jones; Jie Jin Wang; Elena Rochtchina; Chris Howard; Paul Mitchell; Carolyn M Sue
Journal:  Mitochondrion       Date:  2007-01-08       Impact factor: 4.160

6.  Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.

Authors:  Robert J Adams; Donald Brambilla
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

7.  Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Authors:  A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

8.  Beneficial effect of L-arginine for stroke-like episode in MELAS.

Authors:  Masaya Kubota; Yoichi Sakakihara; Masato Mori; Takanori Yamagata; Mariko Momoi-Yoshida
Journal:  Brain Dev       Date:  2004-10       Impact factor: 1.961

Review 9.  Cerebral arterial pathology of CADASIL and CARASIL (Maeda syndrome).

Authors:  Kunimasa Arima; Sohei Yanagawa; Nobuo Ito; Shu-ichi Ikeda
Journal:  Neuropathology       Date:  2003-12       Impact factor: 1.906

Review 10.  Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young.

Authors:  E Steve Roach; Meredith R Golomb; Robert Adams; Jose Biller; Stephen Daniels; Gabrielle Deveber; Donna Ferriero; Blaise V Jones; Fenella J Kirkham; R Michael Scott; Edward R Smith
Journal:  Stroke       Date:  2008-07-17       Impact factor: 7.914

View more
  1 in total

Review 1.  Clinical neurogenetics: stroke.

Authors:  Natalia S Rost
Journal:  Neurol Clin       Date:  2013-07-17       Impact factor: 3.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.